FDA Alerts and Recalls
Medline Industries, LP convenience kits containing recalled B. Braun Medical bupivacaine hydrochloride components are under an FDA-confirmed Class I correction. Affected families include anterior-hip, C-section, total-knee, posterior-hip, total-hip, navigation, and total-joint kits. Exact lot, UDI, expiration, and distribution details vary by kit and were not fully reproduced on the top-level notice; customers must use Medline's recall letter and inventory records. Initiation preceded the August 20 FDA posting; the publicly reviewed FDA page did not report a final termination date, complete affected-unit denominator, or confirmed injury/death count. Geographic scope is U.S. health-care distribution. The action is company-initiated and FDA-posted/confirmed, not FDA-mandated. Recommended action: quarantine affected kits, remove the recalled B. Braun bupivacaine component, follow Medline instructions, and report adverse events through MedWatch.
What changed
FDA's materially active August 20 notice confirmed a Class I correction for Medline convenience kits containing recalled B. Braun bupivacaine components. Mandatory scan also reviewed FDA recalls and safety alerts, enforcement reports, drug and device safety communications, MedWatch, CBER, and food, biologic, cosmetic, and outbreak notices; no later notice displaced this as the most material newly posted alert in the window.
Why it matters
Affected surgical and obstetric kits may expose patients to recalled injectable bupivacaine components, creating risk of serious injury or death if kits are used without correction.
What to watch next
FDA enforcement-status updates, Medline completion reports, MedWatch signals, and recall termination notices.
What we know
- FDA posted the notice on August 20, 2026.
- Medline Industries issued a correction letter for multiple convenience-kit families containing components affected by B. Braun Medical's bupivacaine recall.
- This is a correction, not wholesale removal of the kits: affected bupivacaine components must be removed before continued use.
- FDA identified the action as Class I, its most serious recall category, meaning use without correction may cause serious injury or death.
Material unknowns
- Complete lot, UDI, expiration, and unit counts across every kit configuration.
- Customer correction completion rate.
- Whether subsequent adverse-event investigation will identify confirmed injuries.
U.S. strategic assessment
High interestFDA's objective is rapid removal of recalled components while preserving usable kits. The notice is an FDA-confirmed company correction, not an FDA-mandated seizure and not merely an adverse-event signal.
Objectives
- Prevent use of affected bupivacaine components.
- Ensure hospitals identify and correct all affected convenience kits.
- Maintain transparent postmarket communication.
Strategy
- Publish Class I recall notice.
- Require customer inventory review and component removal.
- Continue enforcement-report and adverse-event monitoring.
Outcomes
- FDA publicly confirmed the recall and its Class I severity.
- Medline instructed customers to remove affected components before use.
- Confirmed illnesses, injuries, and deaths attributable to the Medline kits were not reported in the notice.
Risks
- Failure to identify nested recalled components inside assembled kits.
- Use of affected bupivacaine during surgery or obstetric procedures.
- Supply disruption if institutions discard complete kits rather than correct them.
Sources
01Primary recall classification, status, hazard, and recommended action
Product-specific Class I correction notice
Event and product-level identifier cross-check
Manufacturer/distributor customer instructions; interested-party source
Hospital-sector dissemination of FDA Class I recall information